Stifel analyst Alex Thompson raised the firm’s price target on Morphic (MORF) to $57 from $30 and keeps a Hold rating on the shares. The firm is updating its model to reflect the recently-announced Eli Lilly (LLY) acquisition for $57 per share, telling investors that it views the likelihood of deal close as high.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: